University of Leicester
Browse

Expert opinion on a safe same day discharge strategy as standard of care after leadless pacemaker implantation

Download (2.15 MB)
journal contribution
posted on 2025-06-02, 14:16 authored by Riyaz Somani, James Daniels, Alexis Mechulan, Vincent Paul, David Sharman, Ka Yan Shirley SzeKa Yan Shirley Sze, Xavier Viñolas Prat
Introduction: Leadless pacemaker (LPs) is a safe and effective alternative to conventional transvenous pacing. There is currently no guidance on which patients could be safely discharged the same day post-procedure. Purpose: To provide guidance to medical teams regarding safe same day discharge (SDD) after LP implantation. Methods: An Advisory Board (AB) of 6 expert Micra™ implanters was formed. Interviews were conducted with each member to understand their experience on patient selection, care pathway, complications, and follow-up of Micra™ implanted patients. This information was used to develop a patient pathway for safe SDD after Micra™ implantation. A further survey was conducted to obtain consensus regarding decision points within the pathway. Results: The SDD after Micra™ Implantation Patient Pathway consists of four phases: Pre-procedure assessment: Social factors are key in deciding suitability of SDD (6/6 AB members agreed, 100%). Patient's comorbidities, frailty status and timing of procedure are also important in decision-making for SDD. Micra™ implant: Ultrasound-guidance reduces vascular access-related complications, increasing the likelihood for SDD (100%). Post-procedure observation: Peri-procedural complications such as pericardial effusion, severe vascular complications, bleeding from access site and device complications would prevent SDD (100%). Patients should complete 6 h of observation prior to discharge (100%). Follow-up: First follow-up should be in-person, 1–4 weeks post-procedure (84 %). Long-term follow-up should be organised as per Micra™ standard of care at each centre (100 %). Conclusions: SDD after Micra™ Implantation Patient Pathway was developed via expert consensus. Adoption of the pathway in clinical practice may facilitate safe SDD after Micra™ Implantation.

History

Author affiliation

College of Life Sciences Cardiovascular Sciences

Version

  • VoR (Version of Record)

Published in

IJC Heart & Vasculature

Volume

58

Pagination

101649 - 101649

Publisher

Elsevier BV

issn

2352-9067

eissn

2352-9067

Copyright date

2025

Available date

2025-06-02

Spatial coverage

Ireland

Language

en

Deposited by

Dr Shirley Sze

Deposit date

2025-05-07

Usage metrics

    University of Leicester Publications

    Licence

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC